外科理论与实践 ›› 2023, Vol. 28 ›› Issue (01): 53-57.doi: 10.16139/j.1007-9610.2023.01.09
收稿日期:
2022-11-18
出版日期:
2023-01-25
发布日期:
2023-03-25
通讯作者:
袁菲
E-mail:daphny2014@163.com
Received:
2022-11-18
Online:
2023-01-25
Published:
2023-03-25
Contact:
YUAN Fei
E-mail:daphny2014@163.com
摘要:
EB病毒阳性的胃癌与伴有淋巴样间质的胃癌均属于胃癌特殊病理亚型。其组织学形态、免疫学与遗传学特征存在部分重叠,却不完全相同。因此,这一组肿瘤不仅引起病理医师诊断上的困惑,同时也不利于临床治疗及后续研究。本文对这两种肿瘤以及与之相近诊断术语作详细介绍及对比,探讨其临床病理特征、遗传学改变、分子检测及治疗进展,并归纳总结现存争议及未来研究方向。
中图分类号:
邓仕杰, 袁菲. EB病毒阳性的胃癌与伴有淋巴样间质的胃癌——诊断及分子检测进展[J]. 外科理论与实践, 2023, 28(01): 53-57.
DENG Shijie, YUAN Fei. Advances in diagnosis and molecular detection of EBV-positive gastric cancer and gastric cancer with lymphoid stroma[J]. Journal of Surgery Concepts & Practice, 2023, 28(01): 53-57.
[1] |
MURPHY G, PFEIFFER R, CAMARGO M C, et al. Meta-analysis shows that prevalence of Epstein-Barr virus-positive gastric cancer differs based on sex and anatomic location[J]. Gastroenterology, 2009, 137(3):824-833.
doi: 10.1053/j.gastro.2009.05.001 pmid: 19445939 |
[2] |
LEE J H, KIM S H, HAN S H, et al. Clinicopathological and molecular characteristics of Epstein-Barr virus-associated gastric carcinoma: a meta-analysis[J]. J Gastroenterol Hepatol, 2009, 24(3):354-365.
doi: 10.1111/jgh.2009.24.issue-3 URL |
[3] |
LIM H, PARK Y S, LEE J H, et al. Features of gastric carcinoma with lymphoid stroma associated with Epstein-Barr virus[J]. Clin Gastroenterol Hepatol, 2015, 13(10):1738-1744.
doi: 10.1016/j.cgh.2015.04.015 URL |
[4] |
SETIA N, AHN S, HAN H S, et al. Predictive value of WHO classification for PD-L1 and Her2/Neu expression and distinct associations with protein expression based classification in gastric carcinoma[J]. Hum Pathol, 2019, 94:64-70.
doi: S0046-8177(19)30184-4 pmid: 31676362 |
[5] |
KIM S T, CRISTESCU R, BASS A J, et al. Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer[J]. Nat Med, 2018, 24(9):1449-1458.
doi: 10.1038/s41591-018-0101-z pmid: 30013197 |
[6] |
Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma[J]. Nature, 2014, 513(7517):202-209.
doi: 10.1038/nature13480 |
[7] |
PULIGA E, CORSO S, PIETRANTONIO F, et al. Microsatellite instability in gastric cancer: between lights and shadows[J]. Cancer Treat Rev, 2021, 95:102175.
doi: 10.1016/j.ctrv.2021.102175 URL |
[8] |
AJANI J A, D'AMICO T A, BENTREM D J, et al. Gastric cancer, version 2.2022, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2022, 20(2):167-192.
doi: 10.6004/jnccn.2022.0008 URL |
[9] |
LORDICK F, CARNEIRO F, CASCINU S, et al. Gastric cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up[J]. Ann Oncol, 2022, 33(10):1005-1020.
doi: 10.1016/j.annonc.2022.07.004 pmid: 35914639 |
[10] |
FUKAYAMA M, USHIKU T. Epstein-Barr virus-associated gastric carcinoma[J]. Pathol Res Pract, 2011, 207(9):529-537.
doi: 10.1016/j.prp.2011.07.004 pmid: 21944426 |
[11] |
CHEN J N, HE D, TANG F, et al. Epstein-Barr virus-associated gastric carcinoma: a newly defined entity[J]. J Clin Gastroenterol, 2012, 46(4):262-271.
doi: 10.1097/MCG.0b013e318249c4b8 URL |
[12] |
SHINOZAKI-USHIKU A, KUNITA A, FUKAYAMA M. Update on Epstein-Barr virus and gastric cancer (review)[J]. Int J Oncol, 2015, 46(4):1421-1434.
doi: 10.3892/ijo.2015.2856 URL |
[13] |
YAMADA L, SAITO M, THAR MIN A K, et al. Selective sensitivity of EZH2 inhibitors based on synthetic letha-lity in ARID1A-deficient gastric cancer[J]. Gastric Cancer, 2021, 24(1):60-71.
doi: 10.1007/s10120-020-01094-0 |
[14] |
MIMURA K, TEH J L, OKAYAMA H, et al. PD-L1 expression is mainly regulated by interferon gamma associa-ted with JAK-STAT pathway in gastric cancer[J]. Cancer Sci, 2018, 109(1):43-53.
doi: 10.1111/cas.2018.109.issue-1 URL |
[15] |
NAKANO H, SAITO M, NAKAJIMA S, et al. PD-L1 overexpression in EBV-positive gastric cancer is caused by unique genomic or epigenomic mechanisms[J]. Sci Rep, 2021, 11(1):1982.
doi: 10.1038/s41598-021-81667-w pmid: 33479394 |
[16] |
HISSONG E, RAMRATTAN G, ZHANG P, et al. Gastric carcinomas with lymphoid stroma: an evaluation of the histopathologic and molecular features[J]. Am J Surg Pathol, 2018, 42(4):453-462.
doi: 10.1097/PAS.0000000000001018 pmid: 29438172 |
[17] |
GONZALEZ R S, CATES J M M, REVETTA F, et al. Gastric carcinomas with lymphoid stroma: categorization and comparison with solid-type colonic carcinomas[J]. Am J Clin Pathol, 2017, 148(6):477-484.
doi: 10.1093/ajcp/aqx096 pmid: 29126141 |
[18] |
KANG W, TO K F. Are Epstein-Barr virus-positive and-negative gastric carcinomas, with lymphoid stroma, single entity or different entities?[J]. Clin Gastroenterol Hepatol, 2015, 13(10):1745-1747.
doi: 10.1016/j.cgh.2015.06.024 URL |
[19] |
KONO K, NAKAJIMA S, MIMURA K. Current status of immune checkpoint inhibitors for gastric cancer[J]. Gastric Cancer, 2020, 23(4):565-578.
doi: 10.1007/s10120-020-01090-4 pmid: 32468420 |
[20] |
TORRE L A, SIEGEL R L, WARD E M, et al. Global cancer incidence and mortality rates and trends—an update[J]. Cancer Epidemiol Biomarkers Prev, 2016, 25(1):16-27.
doi: 10.1158/1055-9965.EPI-15-0578 URL |
[21] |
GBD 2017 Stomach Cancer Collaborators. The global, regional, and national burden of stomach cancer in 195 countries, 1990-2017: a systematic analysis for the Global Burden of Disease study 2017[J]. Lancet Gastroenterol Hepatol, 2020, 5(1):42-54.
doi: 10.1016/S2468-1253(19)30328-0 URL |
[22] | SWEED D, SULTAN M M, MOSBEH A, et al. Lymphoe-pithelioma-like hepatocellular carcinoma: a case report and review of literature[J]. J Gastrointest Cancer, 2021. |
[23] |
WANG J K, JIN Y W, HU H J, et al. Lymphoepithelioma-like hepatocellular carcinoma: a case report and brief review of literature[J]. Medicine (Baltimore), 2017, 96(51):e9416.
doi: 10.1097/MD.0000000000009416 URL |
[24] |
SHINODA M, KADOTA Y, TSUJIKAWA H, et al. Lymphoe-pithelioma-like hepatocellular carcinoma: a case report and a review of the literature[J]. World J Surg Oncol, 2013, 11:97.
doi: 10.1186/1477-7819-11-97 |
[1] | 朱正纲. 胃癌外科综合治疗的若干进展与展望[J]. 外科理论与实践, 2023, 28(01): 1-6. |
[2] | 赵法之, 赵平. 胃癌治疗手术中心论体系的形成与完善[J]. 外科理论与实践, 2023, 28(01): 24-30. |
[3] | 李国立, 郭飞龙. 动静脉结合术前化疗在进展期胃癌治疗中的应用[J]. 外科理论与实践, 2023, 28(01): 31-35. |
[4] | 刘文韬, 刘福坤. 中国胃癌围术期综合治疗概述与展望[J]. 外科理论与实践, 2023, 28(01): 36-41. |
[5] | 张欢, 陈勇. 影像组学在胃癌诊断中的新进展[J]. 外科理论与实践, 2023, 28(01): 42-48. |
[6] | 李建芳, 余俊贤, 严超, 朱正纲, 刘炳亚. 胃癌基础与转化研究的热点问题[J]. 外科理论与实践, 2023, 28(01): 7-16. |
[7] | 卢一鸣, 熊建平, 田艳涛. 晚期胃癌转化治疗的发展现状与研究前景[J]. 外科理论与实践, 2023, 28(01): 17-23. |
[8] | 陈平, 徐莹, 吴云林. 消化内镜在早期胃癌诊断中的应用进展[J]. 诊断学理论与实践, 2022, 21(05): 551-554. |
[9] | 王亚雷. 重视胃癌高危人群的内镜精查[J]. 诊断学理论与实践, 2022, 21(05): 555-559. |
[10] | 马乾宸, 张本炎, 芮炜玮, 王婷, 罗方秀, 王朝夫, 袁菲. 中国3 071例胃癌病理分型分析[J]. 诊断学理论与实践, 2022, 21(05): 560-566. |
[11] | 杨蕊馨, 杜宇童, 燕然林, 朱正纲, 李琛, 于颖彦. 消化道肿瘤单细胞转录组测序研究中生物样本前处理改良的探索[J]. 诊断学理论与实践, 2022, 21(05): 567-574. |
[12] | 戴志强, 郑金鑫, 唐兆庆, 张启, 顾远, 史忠义, 胡国华, 孙益红. 淋巴结转移率对Ⅱ~Ⅲ期胃癌根治术后病人预后的评估[J]. 外科理论与实践, 2022, 27(05): 429-434. |
[13] | 鲍萍萍, 吴春晓, 顾凯, 庞怡, 王春芳, 施亮, 向詠梅, 龚杨明, 窦剑明, 吴梦吟, 付晨, 施燕. 上海市2016年胃癌发病特征及2002年至2016年胃癌发病趋势分析[J]. 诊断学理论与实践, 2022, 21(04): 462-469. |
[14] | 李娜娜, 齐涛, 朱黎明. 血清胃蛋白酶原、胃泌素17和幽门螺杆菌IgG抗体在胃部疾病初筛中的临床价值[J]. 诊断学理论与实践, 2022, 21(04): 509-513. |
[15] | 聂明明, 朱正纲. 腹腔镜探查对进展期胃癌精准分期的临床意义[J]. 外科理论与实践, 2022, 27(04): 365-370. |
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||